Thrivent Financial for Lutherans Has $709,000 Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Thrivent Financial for Lutherans decreased its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 1.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,828 shares of the specialty pharmaceutical company’s stock after selling 200 shares during the period. Thrivent Financial for Lutherans owned about 0.06% of ANI Pharmaceuticals worth $709,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of ANIP. Charles Schwab Investment Management Inc. increased its holdings in ANI Pharmaceuticals by 3.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 250,346 shares of the specialty pharmaceutical company’s stock valued at $14,936,000 after purchasing an additional 8,869 shares in the last quarter. FMR LLC increased its stake in shares of ANI Pharmaceuticals by 27.5% in the third quarter. FMR LLC now owns 18,401 shares of the specialty pharmaceutical company’s stock valued at $1,098,000 after buying an additional 3,972 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of ANI Pharmaceuticals by 24.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after buying an additional 579 shares during the last quarter. Public Sector Pension Investment Board increased its position in ANI Pharmaceuticals by 4.4% in the 3rd quarter. Public Sector Pension Investment Board now owns 35,229 shares of the specialty pharmaceutical company’s stock valued at $2,102,000 after acquiring an additional 1,500 shares in the last quarter. Finally, HighTower Advisors LLC bought a new position in shares of ANI Pharmaceuticals in the third quarter worth about $222,000. 76.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. JPMorgan Chase & Co. began coverage on ANI Pharmaceuticals in a report on Wednesday, March 12th. They set an “overweight” rating and a $85.00 price objective for the company. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. Jefferies Financial Group began coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 14th. They set a “buy” rating and a $80.00 price target for the company. Finally, Guggenheim increased their price objective on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, March 5th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $79.75.

Insider Transactions at ANI Pharmaceuticals

In other news, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $60.20, for a total value of $60,200.00. Following the completion of the transaction, the senior vice president now owns 68,624 shares in the company, valued at $4,131,164.80. The trade was a 1.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Meredith Cook sold 400 shares of the stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the transaction, the vice president now directly owns 80,545 shares in the company, valued at $5,100,914.85. The trade was a 0.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 3,200 shares of company stock worth $191,776. Insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Trading Up 2.0 %

ANI Pharmaceuticals stock opened at $69.36 on Thursday. The firm’s fifty day moving average price is $61.08 and its 200-day moving average price is $58.64. The stock has a market cap of $1.51 billion, a P/E ratio of -126.11 and a beta of 0.63. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $70.00.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.